Parabilis Medicines

The Helicon platform enables the design of stabilized helical peptides for cell penetration and specific binding to intracellular protein targets.

The Helicon platform combines computation, experimentation, and digitization to create a scalable drug discovery engine for peptide therapeutics.

The company describes how its Helicon platform enables efficient discovery and optimization of peptides for intracellular targets.

Parabilis Medicines aims to develop medicines with life-changing impact for patients and their caregivers.

mRNA display enables the discovery of high-diversity peptide binders through large library sizes and direct access to functional peptides. However, technical complexity and specialized techniques often prevent labs from advancing beyond initial exploration.

This fall, we shared the first clinical data on our beta-catenin:TCF inhibitor, FOG-001, at a series of medical meetings. In the coming months and years, more releases will follow, both for FOG-001 and the new candidates we are advancing in our pipeline. These will typically be formal and focused, usually in the form of presentations or posters. But in summarizing the high-level outcomes of the complex and multi-year efforts that go into discovering a new drug, these publications are necessarily

Mutations in the Wnt/β-catenin pathway drive millions of cancer cases annually, including colorectal and rare tumors like desmoid and adamantinomatous craniopharyngioma (ACP). The pathway’s β-catenin:TCF complex has historically been considered undruggable.

Parabilis Medicines develops transformational therapies for cancer and serious diseases, aiming to change treatment paradigms for patients worldwide.

Alan Sebulsky has over 40 years of experience in biopharmaceutical investment, financial strategy, and board leadership, most recently as Partner at Adage Capital Management.

Alexis Borisy is a biotech entrepreneur and investor with 30 years of experience founding and investing in science-based companies, including Curie.Bio and IDRx.

Edward Fitzgerald has over 40 years of experience in biotechnology and pharmaceutical finance, including roles as CFO and treasurer at ARIAD Pharmaceuticals from 2002 to 2016.

Jake Simson is a Partner at RA Capital Management, investing in public and private biotech companies and serving on boards including Janux Therapeutics, Tyra Biosciences, and Bicara Therapeutics. He holds degrees in materials science and biomedical engineering.

Formerly known as Fog Pharmaceuticals, Parabilis Medicines was founded in 2015 to address a fundamental gap in modern drug development: the great progress that has been made in identifying human disease targets has not been matched by advances in the ability to develop medicines for them.

The company has pioneered a new class of alpha-helical peptides – Helicons – capable of modulating intracellular proteins that have historically been beyond the reach of conventional medicines.

Parabilis Medicines outlines its privacy practices for user data collected on parabilismed.com.